Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.61 -0.27 (-0.27%)
Streaming Delayed Price Updated: 2:44 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
94 95 Next >
3 No-Brainer Dividend Stocks to Buy in September
These stocks pay great dividends and could be long-term winners. 
Via The Motley Fool
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant? 
Via MarketBeat
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out? 
Via MarketBeat
Exposures Product Safety
What's Wrong With Merck's Stock?
Is the healthcare stock an underrated buy right now? 
Via The Motley Fool
(MRK) - Analyzing Merck & Co's Short Interest
Via Benzinga
What's Going On With Merck Shares Thursday?
Merck stock is trading higher on Thursday after the company announced it completed negotiations with the pan-Canadian Pharmaceutical Alliance. 
Via Benzinga
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Could this beaten-down stock turn things around in the near future? 
Via The Motley Fool
The Smartest Dividend Stocks to Buy With $5,000 Right Now
These stocks have a long history of increasing dividends. 
Via The Motley Fool
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
From Merck & Co., Inc.
Via Business Wire
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock. 
Via Chartmill
Comparing Merck &amp; Co With Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
From Merck & Co., Inc.
Via Business Wire
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals. 
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Options: An Unlikely Source Of Income
Calls give the buyer the right, but not the obligation, to buy a stock at a specific price by a specific date. The seller of the call must deliver the stock if the buyer requests it. 
Via Talk Markets
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
From Merck & Co., Inc.
Via Business Wire
2 Dividend Stocks You Can Safely Hold Through a Recession
These stocks can help you sleep peacefully at night, even in bad times. 
Via The Motley Fool
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
Via Benzinga
Exposures COVID-19
Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data
Merck discontinues two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, for Keytruda in lung cancer and cutaneous squamous cell carcinoma. Independent committees found no survival benefit and higher... 
Via Benzinga
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
From Merck & Co., Inc.
Via Business Wire
Dow Jones Industrial Average Pares Recent Gains As Investors Take A Pause
The Dow Jones Industrial Average (DJIA) trimmed near-term gains on Wednesday, backsliding 150 points in the midweek market session. 
Via Talk Markets
Topics Stocks
Exposures US Equities
12 Dividend Stocks to Earn Income Every Month
Get paid a dividend on a monthly basis. 
Via The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
There's no reason to succumb to gloom and doom here. 
Via The Motley Fool
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
94 95 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.